New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit …,

In addition to KEYNOTE-799, Merck has initiated the Phase 3 KEYLYNK-012 study (ClinicalTrials.gov, NCT04380636 ), which will evaluate KEYTRUDA …, In addition to KEYNOTE-799, Merck has initiated the Phase 3 KEYLYNK-012 study (ClinicalTrials.gov, NCT04380636 ), which will evaluate KEYTRUDA …, Read More